Research and Markets: Pfizer Inc - Detailed Product Pipeline 2010 Features the Pfizer's Deals and Alliances and Recent Cor

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/5adf51/pfizer_incdetaile) has announced the addition of the "Pfizer Inc-Detailed Product Pipeline" company profile to their offering.

Pfizer Inc - Detailed Product Pipeline contains detailed information on pipelines by phase and therapeutic indication as well as management information, deals and alliances and recent news on the company including key milestones.

Scope of the reports

Each Pipeline Report provides the user with real detail on a company's pipeline.

In addition to business summaries, contact information, company details and selected financial data, each report also contains extensive information in tabular and graphical formats on a company's product pipeline and disease hub classification.

Product details consist of complete descriptions, therapeutic indication, drug class, mechanism of action and clinical trial information. Every report also includes detail on a company's deals and alliances and recent corporate news including key milestones.

Key benefits

Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline. Keep track of your competitors and partners by better understanding their product pipeline. Monitor a company's research effectiveness by determining pipeline depth and numbers of products in development by clinical phase.

Key Topics Covered:

  • Business Summary
  • Headquarters
  • Financials
  • Associated/Subsidiary Companies
  • Product Glance
  • --Products by Phase of Development
  • --Products by Disease Hub Classification
  • --Products by Indication
  • Patent Expirations
  • Upcoming Milestones
  • Company Sales Figures
  • --Product Revenue
  • All Values in US Dollar (in millions)
  • --Revenue by Product Line
  • All Values in US Dollars (in millions)
  • Product Pipeline
  • Product Details
  • Recent Updates
  • --Company Announcements
  • --Deals & Alliances
  • --Financials
  • --Mergers & Acquisitions
  • --Product Updates
  • --Regulatory

For more information visit http://www.researchandmarkets.com/research/5adf51/pfizer_incdetaile

Source: Life Science Analytics



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.